◀ Back to ADCY9
ADCY9 — ADRB2
Text-mined interactions from Literome
Horinouchi et al., Eur J Pharmacol 2002
:
In the
presence of beta1- and
beta2-adrenoceptor blockade, the potency ( pD2 value ) of catecholamines ( ( - ) -isoprenaline, ( - ) -noradrenaline and ( - ) -adrenaline ) and beta(3)-adrenoceptor agonists ( ( R*, R* ) - ( +/- ) -4- [ 2- [ ( 2- ( 3-chlorophenyl ) -2-hydroxyethyl ) amino ] propyl ] phenoxyacetic acid sodium ( BRL37344 ) and ( +/- ) - [ 4- [ 3- [ ( 1,1-dimethylethyl ) amino ] -2-hydroxypropoxy ] -1,3-dihydro-2H-benzimidazol-2-one ] hydrochloride ( ( +/- ) -CGP12177A ) ) to induce relaxation was not affected by the
adenylate cyclase inhibitor, 9- ( tetrahydro-2-furanyl ) -9H-purin-6-amine ( SQ-22,536, 100 microM )
Krasnikova et al., Kardiologiia 1992
(Hypertension) :
The effects of prostaglandin E2 ( PGE2 ) infusions on lymphocyte
beta 2-adrenoceptor dependent
adenylate cyclase ( beta 2ARAC ) system were studied in 26 patients with resistant hypertension ( RH )
Kashles et al., Biochem Pharmacol 1987
(Carcinoma, Squamous Cell) :
Characterization of the
beta 2-adrenoceptor dependent
adenylate cyclase of A431 epidermoid carcinoma cells
Krasnikova et al., Tsitologiia 1994
:
[ The effect of sodium and ouabain on the activation of
beta 2-adrenoreceptor dependent
adenylate cyclase in human lymphocytes ]
Gürdal et al., Mol Pharmacol 1997
:
In previous studies, it was shown that the overexpression of
beta2-adrenoceptor (beta2AR) in the hearts of transgenic mice ( Tg )
leads to agonist independent activation of
adenylate cyclase and enhanced myocardial function